A significant reduction of the level of B-cell activating factor (BAFF) was described after intrathecal administration of rituximab in nine patients of which four with relapsing-remitting MS (RRMS) and five with secondary progressive MS (SPMS) [10]. Here, TNFSF13B is linked to secondary progressive multiple sclerosis.